Gaceta Médica de México

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor


>Revistas >Gaceta Médica de México >Año 2003, No. 4

Millán-Guerrero RO, Pineda-Lucatero AG, Pacheco-Carrasco MF
Migraña. Una revisión de la fisiopatogenia y alternativa terepéutica futura.
Gac Med Mex 2003; 139 (4)

Idioma: Español
Referencias bibliográficas: 58
Paginas: 377-380
Archivo PDF: 67.91 Kb.

[Texto completo - PDF]


Este trabajo contempla descubrimientos recientes sobre la fisiopatogenia de la migraña, enfocándose a la combinación de eventos que se suceden en secuencia para originar la migraña. Se revisaron datos actuales sobre sustancia P, péptido intestinal vasoactivo, histamina, receptores H1, H3 y agonista de los receptores H3; todos ellos neuromoduladores que se encuentran en íntima relación con la migraña. Se expone el tratamiento que se recomienda para migraña y el motivo del fracaso de la terapéutica actual, que con dificultad alcanza el 70% de eficacia. Se contempla el futuro del tratamiento para migraña el cual deberá estar dirigido hacia la búsqueda de fármacos que interaccionen directamente con estos neuromoduladores para poder ofrecer a los pacientes con migraña, medicamentos con mejor eficacia y mínimos efectos indeseables.

Palabras clave: Migraña, fisiopatogenia, histamina, sustancia P.


  1. Sánchez-Magallón MJ, Galiano M, Fernández Y. The headache in general neurological practice. Neurology 2000;15:274-277.

  2. 2. Sistema de Información Médico Operativo. Boletín del Instituto Mexicano del Seguro Social, 2000.

  3. 3. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-657.

  4. 4. Rasmussen BK. Epidemiology of headache. Cephalagia 1995;15:45-68.

  5. 5. Rapaport AM. Update on severe headache with a focus on migraine. Neurology 1994;44(Suppl 3):S5.

  6. 6. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs 1999;159:813-818.

  7. 7. Olesen J. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgia and facial pain. Cephalalgia 1988;8(Suppl 7):1-96.

  8. 8. Breslau N, Rasmussen BK. The impact of migraine. Epidemiology, risk factors and comorbidities. Neurology 2001;56(Suppl 1):S4-S12.

  9. 9. Bartleson JD. Treatment of migraine headaches. Mayo Clinic Proc 1999-74:702-708.

  10. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-163.

  11. Baumel B. Migraine: a pharmacology review with a newer options and the delivery modalities. Neurology 1994;Suppl 3:S13-S17.

  12. Wilkinson M. Treatment of migraine. Headache 1988;28:659-661.

  13. Lance JW. Treatment of migraine. Lancet 1992;339:1207-1209.

  14. Perouta SJ. The pharmacology of current anti-migraine drugs. Headache 1990;30:5-11.

  15. Hoffert MJ. Treatment of migraine: a new era. Am Med Physician 1994;49: 633-638.

  16. Welch KM. Drug therapy of migraine. N Engl J Med 1993;11:1476-1483.

  17. Kozubski W, Prusinski A. Sodium valproate versus propranolol in the prophylactic treatment of migraine. Neurol Neurochim Pol 1995;29 (6):937-947.

  18. Blau JN. Migraine: theories of pathogenesis. Lancet 1992;339: 1203-1207.

  19. Wolff HG. Wolff’s Headache and other head pain. 5th ed. Dalessio DJ.ed. Oxford University Press; New York, 1963.

  20. Lauritzen M. Cerebral blood flow in migraine and cortical spreading depression. Acta Neurol Scand 1987;(Suppl ):113-140.

  21. Strassman AN, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature 1996;384:560-564.

  22. Woods RP, Iacoboni M, Mazziotta JC. Bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994;331:1689-1692.

  23. Baron JC. The pathophysiology of migraine: insights from functional neuroimaging. Rev Neurol (Paris) 2000;156 Human:4S15-4S23.

  24. Chemyshev OY, Vein Alt Mathew NT, Kolosova OA, Kailasam J, Frolov A, Danilov AB, Meadors L, Gentry P, Alexandrov AV. Blood flow velocity and pulsatility index differences in patients with unilateral migraine. Headache 2001;41:704-709.

  25. May A, Goadsby PJ. The trigeminovascular system in humans: pathophysiologic implications for primary headache syndromes of the neural influences on the cerebral circulation. J Cerebral Blood Flow 1999;19-115-127.

  26. Goadsby PJ, Duckworth JW. Effect of stimulation of trigeminal ganglion on regional cerebral blood flow in cats. Am J Physiol 1987;253:R270.R274 (Medline Link).

  27. Feindel W, Penficid W, McNaughton F. The tentorial nerves and localization of intracranial pain in man. Neurology 1960- 10:555-563.

  28. Ray BS, Wolff HG. Experimental studies on headache. Pain sensitive structures of the head and their significance in headache. Arch Surg 1940;41:813-856

  29. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984;16:157-168.

  30. Buzzi MG, Moskowitz MA. The trigemino-vascular system and migraine. Pathol Biol (Paris) 1992;40:313-317.

  31. Hanko J, Hardebo JE, Kahrstrom J, Owman C, Sundler F. Calcitonin gene-related peptide is present in mammalian cerebrovascular nerve fibers and dilates pial and peripheral arteries. Neurosci Lett 1985;57:91-95 (Medline Link).

  32. Coelho AM, Fioramonti J, Bueno L. Mast cell degranulation induces delayed rectal allodynia in rats: role of histamine and 5H-T. Dig Dis Sci 1998;43:727-737.

  33. May A, Goadsby PJ. Substance P receptor antagonist in the therapy of migraine. Expert Opin Investig Drugs 2001;10:673-678.

  34. Iversen L. Pharmacology: substance P equals pain substance? Nature 1998;392:334-335.

  35. Romerio SC, Linder L, Haefeli WE. Neurokinin-I receptor antagonist RI 16301 inhibits substance P-induced venodilation. Clin Pharmacol Ther 1999;66:522-527.

  36. Göthert M, Garbarg M, Hey JA, Schlicker E, Schwartz JC, Levi R. New aspects of the role of histamine in cardiovascular function: identification, characterization, and potential pathophysiological importance of H3 receptors. Can J Physiol Pharmacol 1995;73(5):558-564.

  37. Imamura M, Smith NCE, Garbarg M, Levi R. Histamine H sub 3-receptor mediated inhibition of calcitonin gene related peptide release from cardiac c fibers: Circu Res1996;78:863-869.

  38. Van Der Pouw K, Tineke CTM, Snijders A, Boeije LCM, De Groot ER, et al. Histamine inhibits the production of interleukin-12 through interaction with H2 receptors. J Clin Invest 1998;102:1866-1873.

  39. Kenneth S, Babe Jr, Serafin WE. In: Mohnoff PB, Ruddon RW, Goodman & Gilman, editores. Histamina, bradicina y antagonistas. México: McGraw-Hill Interamericana, 1996. p. 621-641.

  40. Morisset S, Traiffort E, Arrang JM, Schwartz JC. Changes in histamine H3 receptor responsiveness in mouse brain. J Neurochemi 2000;74:339.

  41. Arrang JM, Garbarg M, Schwartz J-C. Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor. Nature 1983; 302:832-837.

  42. Arrang J-M, Garbarg M, Lancelot J-C, Lecomte J-M, Pollard H, Robba M, Schunack W, Schwartz J-C. Highly potent and selective ligands for histamine R3 receptors. Nature 1987;327:117-123.

  43. Ishikawa S, Sperelakis N. A novel class (H3) of histamine receptors on perivascular nerve terminals. Nature 1987;327: 158-160.

  44. West RE, Zweig A, Shih NG, Siegel MI, Egan RW. Identification of two H3 histamine receptor subtypes. Mol Pharmacol 1991-38:610-613.

  45. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks. Pain 2000;86:133-138.

  46. Thomsen LL, Olesen JB. Nitric oxide in primary headaches. Curr Opin Neurol 2001;14:315-321.

  47. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Expert Opin Investig Drugs 2001;10:673-678.

  48. Schlicker E. R, Betz R, Gothert M. Histamine H3 receptor-mediated inhibition of serotonin release in the rat brain cortex. Arch Pharmacol 1988;337:558-590.

  49. Theoharides TC, Spanos C, Pang X, et al. Stress induced intracranial mast cell degranulation: a corticotropin releasing mediated effect. Endocrinology 1995;136(12): 5745-5570.

  50. Dimitriadou V, Rouleau A, Dam Trung Tuong M, Newlands GJF, Miller HRP, Luffau G, Schwartz C, Garbarg M. Functional relationship between mast cells and C-sensitive nerve fibers evidenced by histamine H3-receptor modulation in rat lung and spleen. Clin Sci 1994;87:151-163.

  51. Daugaard D, Thomsen LL, Olesen J. No relation between cephalic venous dilatation and pain in migraine. J Neurol Neurosurg Psychiatry 1998;65:260-262.

  52. Edvinson L., Goadsby PJ. Neuropeptides in the cerebral circulation: relevance to headache. Cephalalgia 1995;15(4): 272-276.

  53. Humphrey PD, Goadsby PJ. The mode of action of sumatriptan in vascular. A debate. Cephalalgia 1994; 14(6):401-410.

  54. Krabbe AA, Olesen J. Headache provocation by continuous intravenous infusion of histamine: clinical results and receptor mechanisms. Pain 1980;8:253-259.

  55. Lassen LH, Thomsen LL, Olesen J. Histamines induce migraine via the Hl receptor support for the NO hypothesis of migraine. Neuroreport 1995;(6):1475-1459.

  56. Millán-Guerrero RO, Isaías CM, Antonio OA, Pacheco-Carrasco W. Histamine as a therapeutic alternative in migraine prophylaxis: a randomized, placebo-controlled, double-blind study. Headache 1999;39:576-580.

  57. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine. Cephalalgia 1991;11:1-12.

  58. Olesen J, Jansen-Olesen I. Nitric oxide mechanism in migraine. Pathol Biol (Paris) 2000;48:648-657.

>Revistas >Gaceta Médica de México >Año2003, No. 4

· Indice de Publicaciones 
· ligas de Interes 

Derechos Resevados 2019